Company news
Can-fite Biopharma Ltd. (TASE:CANF) news
Can-fite Biopharma Ltd. news releases on 6ix. Latest, Sep 8, 2026: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting…
Press releases & updates
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
September 8, 2026
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
May 18, 2026
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
May 13, 2026
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
April 30, 2026
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
March 30, 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
March 26, 2026
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
March 17, 2026
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
March 4, 2026
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
February 17, 2026
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
February 9, 2026
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
February 5, 2026
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
January 20, 2026
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
December 26, 2025
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
December 23, 2025
Can-Fite Provides Update on Clinical and Financial Status
December 16, 2025
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 26, 2025
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
November 24, 2025
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
November 20, 2025
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
November 18, 2025
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
September 15, 2025
Can-Fite Reports H1 2025 Financial Results and Clinical Update
August 28, 2025
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
July 30, 2025
Can-Fite Announces Up To $15.0 Million Public Offering
July 28, 2025
Breakthrough Study from UCLA Demonstrate Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
July 28, 2025
Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
June 16, 2025
Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
May 5, 2025
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
April 17, 2025
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
April 14, 2025
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
April 14, 2025
Can-Fite Reports 2024 Financial Results and Clinical Update
April 14, 2025
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
March 24, 2025
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
March 20, 2025
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
March 19, 2025
Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
March 18, 2025
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
March 3, 2025
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment with Can-Fite's Namodenoson
February 18, 2025